Your shopping cart is currently empty

DEG-35 is a CRBN-dependent bifunctional degrader targeting IKZF2 and CK1α, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. It activates the p53 apoptotic pathway and is applicable for research related to acute myeloid leukemia (AML).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | DEG-35 is a CRBN-dependent bifunctional degrader targeting IKZF2 and CK1α, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. It activates the p53 apoptotic pathway and is applicable for research related to acute myeloid leukemia (AML). |
| In vitro | DEG-35 (10 and 100 nM) induces significant dose-dependent apoptosis and myeloid differentiation in MOLM-13 cells after 2 days. |
| In vivo | The half-life of DEG-35 (ip) in mouse plasma is 2.5 hours. In BL/6 mice transplanted with MLL-AF9 CrbnI391V cells, DEG-35 (ip, 50 mg/kg) slows the progression of leukemia without significant weight loss. |
| Molecular Weight | 443.45 |
| Formula | C25H21N3O5 |
| Cas No. | 2734910-37-1 |
| Smiles | O=C(NC1=CC=C2C(=O)N(CC2=C1)C3C(=O)NC(=O)CC3)C4=CC=C5C=C(OC)C=CC5=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.